(866) 258-2735

C3 Research is a full-service clinical research organization (CRO) founded in 2008. The C3 team works with biotechnology, pharmaceutical, medical device and diagnostic companies and provides comprehensive clinical research development services including regulatory support, clinical trial management, data management, biostats and programming, medical writing, safety management and pharmacovigilance, and medical monitoring.

Mednet and C3 Research have had a long-standing relationship. C3 has been a client partner using iMednet for over 5 years and was an early adopter in the Mednet Value Program (MVP) in 2019.

C3 has been using iMednet’s electronic data capture capabilities to support their clients and they see it as an optimal solution for their biotech partners. The iMednet solution offers the required functionality along with the right mix of flexibility, a customizable platform and depth in reporting capabilities. C3 also leverages other features and native modules available in the platform, such as lab ranges, coding, randomization and ePRO capabilities, depending on individual sponsor requirements.

C3 Research built their business on the principles of quality, integrity, and responsiveness. They’ve grown their business by leveraging best-in-class technology to streamline processes, stay connected, and bring project teams together. Ron Carozza, CEO of C3 Research says it best, “The iMednet EDC solution provides right-sized capabilities and top-line customer service for biotech drug, device and diagnostic clients. It’s easy to use and its versatility allows us to support a variety of study designs across many therapeutic areas.”

Ron and the C3 team joined the Mednet Value Program as part of their strategy to expand their market presence and target companies in earlier stages of development. Numerous member benefits of the program along with co-marketing and co-selling incentives enable C3 to offer an affordable cutting-edge technology solution to their clients who are conducting smaller, earlier phase clinical trials. This expansion into the earlier stage market has enabled them to quickly develop and grow trusted relationships within a new market segment by facilitating access to technologies that weren’t previously available or affordable to these smaller companies.

Ron noted, “We value the Mednet partnership. We love the technology, its ease of use and versatility. Joining the MVP was an easy decision that made good business sense because it aligned so well with our own business and growth goals.”
C3 Research’s commitment to quality, integrity and responsiveness is clear in their enthusiastic participation in the MVP and how quickly and seamlessly they were able to offer an innovative, high quality, technology-enabled service in response to market demand.

As their preferred technology partner, the Mednet team is excited to see C3 Research’s continued growth and their support for small and mid-sized companies.


“The MVP is just one example of Mednet’s innovative approach to clinical trials technology, allowing for wide-spread adoption of technologies not previously available to small to mid-sized clients.”

– RON CAROZZA, CEO, C3 RESEARCH